Barry J. Simon - Jun 9, 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: Director
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Stock symbol: VIRX
Transactions as of: Jun 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/10/2022, 05:16 PM
Previous filing: Mar 25, 2022
Next filing: Jun 9, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+40K		$0.00	40K	Jun 9, 2022	Common Stock	40K	$3.24	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.